The evolving treatment landscape in multiple myeloma and its implications for clinical practice

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK discusses the evolving treatment landscape of multiple myeloma (MM) and its implications for clinical practice at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. A number of new agents are coming through and due to the age of patients, it is important to consider toxicities and continuous therapy. In the session in which Dr Ramasamy participated, they discussed real life patient case studies; Dr Ramasamy outlines the case of his patient and the question of embarking on a new treatment in someone who has had two previous treatments and experienced side effects. He further discusses the use of ixazomib, lenalidomide and dexamethasone.

Share this video